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Abstract: 
 
Background: The emergence of multi-drug resistant bacterial strains worldwide has necessitated the scientific 
search for novel, potent, and affordable antimicrobial agents including medicinal plants and non-antibiotic drugs for 
therapy of infectious diseases. The objective of this study is to assess in vitro antibacterial activities and time kill 
kinetics of some non-antibiotic drugs against pathogenic clinical bacterial isolates. 
Methodology: In vitro antibacterial activities including minimum inhibitory concentration (MIC), minimum 
bactericidal concentration (MBC) and time kill kinetics of Amlodipine (AML), Thioridazine (THI) and Promethazine 
(PRO) against Staphylococcus aureus, coagulase negative staphylococci (CoNS), Streptococcus spp, Escherichia 
coli, Enterobacter spp, Klebsiella pneumoniae and Pseudomonas aeruginosa clinical isolates were determined using 
disc diffusion, broth microdilution and plate count techniques.   
Results: The mean growth inhibition zones by the disc diffusion assay of AML, THI and PRO against the isolates 
were ≤15.1±1.0 mm with MIC and MBC values ranging from 12.5 to 50µg/ml and 25 to 100µg/ml respectively. The 
time-kill assay revealed bactericidal effect of AML, THI and PRO on Gram positive bacteria evidenced by mean log 
reductions in viable bacterial cell counts ranging from 0.13 Log10 to 2.41 Log10 CFU/ml for S. aureus, 0.88 Log10 to 
2.08 Log10 CFU/ml for Streptococcus spp, and 0.26 Log10 to 2.34 Log10 CFU/ml for CoNS after ≤30hrs post 
inoculation at 1xMIC. The range of log reduction in viable cell counts of Gram-negative bacteria exposed to AML, 
THI and PRO were E. coli (0.11 to 3.23 Log10 CFU/ml), P. aeruginosa (0.52 to 2.56 Log10 CFU/ml), K. pneumoniae 
(0.85 to 3.0 Log10 CFU/ml) and Enterobacter spp (0.38 to 2.08 Log10 CFU/ml) after ≤30 hrs post inoculation at 1x 
MIC.   
Conclusion: These findings demonstrate in vitro antibacterial efficacies and time kill kinetics of AML, THI and PRO 
against pathogenic clinical bacterial isolates, which indicate that these non-antibiotic drugs may be useful 
therapeutic alternatives in the bid to reduce the burden of infectious diseases associated with antibiotic resistant 
pathogens. 
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Abstrait: 
Contexte: L'émergence de souches bactériennes multirésistantes dans le monde a rendu nécessaire la recherche 
scientifique d'agents antimicrobiens nouveaux, puissants et abordables, notamment des plantes médicinales et des 
médicaments non antibiotiques pour le traitement des maladies infectieuses. L'objectif de cette étude est d'évaluer 
les activités antibactériennes in vitro et la cinétique de destruction temporelle de certains médicaments non 
antibiotiques contre les isolats bactériens cliniques pathogènes.                     
Méthodologie: activités antibactériennes in vitro, y compris la concentration minimale inhibitrice (CMI), la 
concentration bactéricide minimale (MBC) et la cinétique de destruction du temps de l'amlodipine (AML), de la 
thioridazine (THI) et de la prométhazine (PRO) contre Staphylococcus aureus, les staphylocoques à coagulase 
négative (CoNS), Streptococcus spp, Escherichia coli, Enterobacter spp, Klebsiella pneumoniae et Pseudomonas 
aeruginosa ont été déterminés en utilisant des techniques de diffusion sur disque, de microdilution en bouillon et de 
numération sur plaque.                                         
Résultats: Les zones moyennes d'inhibition de la croissance par le test de diffusion de disque d'AML, THI et PRO 
contre les isolats étaient ≤15,1±1,0mm avec des valeurs MIC et MBC allant de 12,5 à 50µg/ml et de 25 à 100µg/ml 
respectivement. Le dosage temporel a révélé un effet bactéricide de la LMA, du THI et du PRO sur les bactéries 
Gram positives, mis en évidence par des réductions logarithmiques moyennes du nombre de cellules bactériennes 
viables allant de 0,13 Log10 à 2,41 Log10 CFU/ml pour S. aureus, 0,88 Log10 à 2,08 Log10 CFU/ml pour 
Streptococcus spp et 0,26 Log10 à 2,34 Log10 CFU/ml pour CoNS après ≤ 30 heures après l'inoculation à 1 x MIC. 
La plage de réduction logarithmique du nombre de cellules viables de bactéries à Gram négatif exposées à la LMA, 
au THI et au PRO était E. coli (0,11 à 3,23 Log10 CFU/ml), P. aeruginosa (0,52 à 2,56 Log10 CFU/ml), K. 
pneumoniae (0,85 à 3,0 Log10 CFU/ml) et Enterobacter spp (0,38 à 2,08 Log10 CFU/ml) après ≤ 30 heures après 
l'inoculation à 1 x MIC.                         
Conclusion: Ces résultats démontrent une efficacité antibactérienne in vitro et une cinétique de destruction du 
temps des LMA, THI et PRO contre les isolats bactériens cliniques pathogènes, ce qui indique que ces médicaments 
non antibiotiques peuvent être des alternatives thérapeutiques utiles dans le but de réduire le fardeau des maladies 
infectieuses associées aux antibiotiques pathogènes résistants. 
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Introduction: 
 
 Although the pharmaceutical industries 
are still in the business of producing new 
antibiotics for treatment of infectious diseases, 
the numbers of infections caused by resistant 
microorganisms continue to increase owing to 
combinations of microbial characteristics and 
selective pressure created by antimicrobial use 
(1,2). The mechanisms of microbial resistance 
to antimicrobial agents include the production 
of structure-inactivating enzymes, alteration of 
cell wall, cell membrane and enzyme (e.g. DNA 
gyrase) target sites and ribosomal modification 
(3). The emergence of multi-drug resistant 
(MDR) microbial strains has necessitated the 
scientific search for potent, novel and afford- 
able antimicrobial agents including plants (4,5) 
and non-antibiotic drugs for the treatment of 
infectious diseases. 
         Scores of non-antibiotic drugs, pharma- 
ceutical preparations belonging to different 
pharmacological classes, currently used in the 
treatment of non-infectious diseases have been 
reported to exhibit both in vitro and in vivo 
antimicrobial activities (6). The non-antibiotic 
drugs, which inhibit microbial metabolism (7), 
with either biocidal or biostatic activity include 
anti-psychotics (thioridazine, clozapine), anti- 
hypertensives (nifedipine and amlodipine) (8), 
non-steroidal anti-inflammatory drugs (ibupro- 
fen, diclofenac sodium) (9), pump inhibitors 
(esomeprazole, omeprazole), anti-histamines 
(promethazine, trimeprazine) (10), and anti- 
depressants (sertraline and paroxetine) (11).  
 Promethazine is usually administered 
to attenuate inflammatory process in disease 
conditions such as allergic rhinitis, conjunct- 
ivitis, and urticaria (12,13). The use of anti-
histamines, especially the first-generation 
phenothiazine H1-inhibitors such as prome- 
thazine for patients with microbial infection 
may become inevitable and this has prompted 
the evaluation of their antimicrobial properties. 
 The antibacterial activity of amlodipine, 
a cardiovascular drug, was reported by Kumar 
et al., (8) on several clinical bacterial isolates 
including Staphylococcus aureus, Escherichia 
coli, Vibrio spp, Salmonella spp, Bacillus spp 
and Pseudomonas aeruginosa. Similarly, in 
addition to the antipsychotic properties of 
thioridazine, significant antimicrobial activities 
against intracellular microorganisms have been 
reported (14). The objective of this study is to 




determine the antibacterial activities and time 
kill kinetics of amlodipine, thioridazine and pro- 
methazine against selected pathogenic clinical 
bacterial isolates.  
 
Materials and method: 
 
Identification of bacterial isolates 
 Fourteen (14) clinical bacterial isolates 
comprising Staphylococcus aureus (n=2), coa- 
gulase negative staphylococci (n=2), Strepto- 
coccus spp (n=2), Escherichia coli (n=2), Kleb- 
siella pneumoniae (n=2), Enterobacter spp (n= 
2), and Pseudomonas aeruginosa (n=2) were 
obtained from the Department of Microbiology, 
University of Uyo, Akwa Ibom State, Nigeria. 
These bacteria were isolated from clinical 
specimens and identified using conventional 
morphological and biochemical tests (15). 
 
Source of the non-antibiotic drugs (Amlodipine, 
Thioridazine and Promethazine) 
 Amlodipine (AML, MAF India Pharma- 
ceutical, India), Thioridazine (THI, Indian Gen- 
eric Company, India) and Promethazine (PRO, 
CSC Pharmaceuticals International, India) were 
purchased in tablet forms from registered 
Pharmacy stores in Uyo. Stock solution of each 
drug was prepared by dissolving 1g of each in 
100ml of sterile distilled water to give a 
concentration of 10mg/ml. The stock solution 
was further diluted to produce 5mg/ml and 2.5 
mg/ml concentrations for each of AML, THI and 
PRO.  
 
Determination of antibacterial activity of the 
non-antibiotic drugs by disc diffusion assay  
 The antibacterial activities of AML, THI 
and PRO on the clinical bacterial isolates were 
determined by the disc diffusion method (16). 
Paper discs of AML, THI and PRO were pre- 
pared by punching sterile Whatman filter paper 
(No.1) with a 6 mm disc puncher and sterili- 
zing them at 160°C for one hour. Each disc was 
then impregnated with 10μL of 2.5mg/ml and 
5.0mg/ml concentrations of AML, THI and PRO 
to give disc contents of 25µg and 50µg 
respectively.     
 Mueller-Hinton agar (MHA) plates were 
aseptically prepared and 0.1ml of each bac- 
terial inoculum, prepared directly from an 
overnight nutrient agar plate and adjusted to 
0.5 McFarland standards, was inoculated using 
sterile pipette onto each of the MHA plate. The 
impregnated discs were carefully placed on the 
MHA plates and incubated aerobically at 37oC 
for 24 hours followed by measurement of the 
diameters of zone of inhibition (in millimetres) 
using a calibrated ruler. The disc diffusion 
assays were performed in triplicates and the 
mean diameters of zones of inhibition were 
recorded.   
 
Determination of minimum inhibitory (MIC) and 
minimum bactericidal concentration (MBC)  
 The MICs of AML, THI and PRO against 
the bacterial isolates were determined using 
macrobroth dilution technique in test tubes (5). 
One ml of the stock solution (10mg/ml) of AML, 
THI and PRO was serially diluted in test tubes 
to obtain concentrations of 5, 2.5, 1.25 and 
0.625mg/ml for each of the non-antibiotic 
solution. To 0.1ml (100µL) of each of these 
concentrations was added 9.9ml nutrient broth 
(1 in 100 dilution) to give the final concen- 
trations of AML, THI and PRO of 100, 50, 25, 
12.5 and 6.25µg/ml for the MIC testing. A 
loopful of prepared inoculum of each bacterium 
was added to each of the non-antibiotic 
solution. A tube containing only nutrient broth 
was inoculated with bacterial isolate to serve as 
control. All culture tubes were incubated 
aerobically at 37oC for 24 hours, after which 
the tubes were examined for microbial growth 
by observing for turbidity. The MIC was read as 
the least concentration of the non-antibiotic 
solution that visibly inhibited the growth of the 
test bacterial isolate after 24 hours incubation.   
 For the MBC, an aliquot of 1ml from 
each of the MIC broth tubes that showed no 
visible growth was streak-inoculated onto 
sterile nutrient agar plates using a sterile 
pipette. The inoculated plates were inverted 
and incubated at 37°C aerobically for 24 hours. 
The MBC values of AML, THI and PRO were 
considered as the concentration of each non-
antibiotic solution that resulted in killing of the 
bacterial isolates, which showed as no visible 
colonies on the agar plates.   
 
Time-kill analysis   
 The time-kill analysis was carried out 
using macrobroth dilution and pour plate 
techniques. An overnight nutrient broth culture 
of each bacterial isolate in test tube was 
adjusted to 0.5 McFarland turbidity standard to 
obtain a starting inoculum of between 105 and 
106 CFU/ml (confirmed by quantitative plate 
counts). The tubes were incubated at 37oC with 
shaken at 150 rpm for 90 mins to ensure that 
microbial growths were in the logarithmic 
(exponential) phase. One (1) millilitre of this 
exponentially growing bacterial cultures was 
added to 9ml of MHB containing MIC concen- 
tration (1ml) of AML, THI and PRO. Bacterial 
growth was quantified at time ‘0’ hour and at 




6, 12, 18, 24, and 30 hours of incubation by 
aseptically taking 1ml of the aliquot, diluting 
serially (10-fold dilutions) in sterile normal 
saline and plating out 1ml of the final dilution 
onto nutrient agar plates. The plates were 
incubated aerobically for 24 hours at 37oC after 
which the colonies on each plate were enu- 
merated and viable cells expressed as CFU/ml. 
Inoculated medium without AML, THI and PRO 
was also set up and plated on nutrient agar as 
control. All experiments were performed in 
triplicates.  
 The percentage and logarithm reduc- 
tions of the bacterial cells exposed to AML, THI 
and PRO were calculated for each of the time 
intervals. The Log10 CFU/ml of survived bac- 
terial cells against exposure time (in hours) 
were plotted on a semi-logarithm graph for 
each bacterial pathogen to obtain the time–kill 
curve. Activity of the non-antibiotic drugs was 
considered bactericidal at the lowest concen- 
tration that reduced the initial inoculum by 
>3Log10 CFU/ml (99.9% killing). The percen- 
tage and logarithm reductions of the bacterial 
cells exposed to AML, THI and PRO were 
respectively calculated as; percentage reduc- 
tion = (initial counts – counts at ‘x’ interval)/ 
initial counts (multiply by 100), while the 
logarithm reduction = Log10 (initial counts) – 
Log10 (counts at ‘x’ interval).        
 
Statistical analysis 
 All experiments were performed in 
triplicates and data analysis was done with the 
Statistical Package for the Social Sciences 
(SPSS) version 20.0. Data were presented as 
mean ± SD and comparison between mean 
values was done using the Duncan multiple 
range test, with significance level at p<0.05.  
 
Results: 
     
 The mean growth inhibitory zone of 
AML against Gram-positive bacteria (GPB) 
ranged from 10.1±0.2mm (25µg disk) to 13.6 
±0.5mm (50µg disk), and against Gram-nega- 
tive bacteria (GNB), from 10.8±0.2mm (25µg 
disk) to 14.5±0.5mm (50µg disk). The mean 
growth inhibitory zone of THI against GPB 
ranged from 8.8±0.1mm (25µg disk) to 14.1 
±0.5mm (50µg disk) and against GNB, from 
10.2±0.2mm (25µg disk) to 14.7±1.0mm (50 
µg disk). For PRO, the mean growth inhibitory 
zone ranged from 9.3±0.1mm (25µg disk) to 
14.5±0.3mm (50µg disk) against GPB, and 8.3 
±0.1 mm (25 µg disk) to 15.1±1.0mm (50µg) 
against GNB. The mean growth inhibitory zone 











13.6±0.3 to 15.6±0.3 mm against GPB, and 
12.0±0.3 to 16.5±0.5 mm against GNB (Table 
1).  
 The AML, THI and PRO inhibited the 
growth of all the 14 isolates tested with MIC 
values in the range of 12.5 – 50 µg/ml, 12.5 -
50µg/ml and 12.5 - ˃50µg/ml respectively. The 
MIC values of THI were lowest for S. aureus, E. 
coli, K. pneumoniae, Enterobacter spp, P. 
aeruginosa and CoNS. The MBC values of AML, 
THI and PRO were in the range of 25 - 100 µg/ 
ml. The MBC of AML for 78.6% of the bacterial 
isolates tested was 50 µg/ml, the MBC of THI 
for 35.7% of bacterial isolates tested was                 
25 µg/ml while the MBC of PRO for 7.1% of the 
bacterial isolates tested was 100 µg/ml (Table 
2). The results also indicated that both MIC and 
MBC end points obtained by visual reading   
 
for AML on CoNS and K. pneumoniae were 
equal.      
 The bactericidal activity was deemed to 
be present if there was a ≥ 99.9% reduction in 
survival from the original inoculum (≥99.9% 
killing). Table 3 showed the percentage and log 
reductions in GPB cells exposed to AML, THI 
and PRO at 6 hours intervals after incubation. 
The percentage and log reduction in viable cell 
counts of S. aureus exposed to AML ranged 
from 33.3 to ≥ 99.9% and 0.18 to 2.41 Log10 
CFU/ml after 30 hrs of interaction respectively 
while the percentage and log reduction in 
viable cell counts of Streptococcus spp exposed 
to AML ranged from 86.96 to ≥ 99.9% and 
0.88 to 2.08 Log10 CFU/ml after 30 hours of 
interaction respectively. 
 The lowest percentage and logarithm
 








reduction in viable cell count of CoNS exposed 
to AML was ≥ 58.6% and 0.38 Log10 CFU/ml 
respectively. The log reduction in viable cell 
counts of S. aureus, Streptococcus spp and 
CoNS exposed to PRO for 30 hrs ranged from 
0.13 to 1.54 Log10 CFU/ml, 0.26 to 2.08 Log10 
CFU/ml and 0.26 to 2.20 Log10 CFU/ml 
respectively (Table 3).  At 1xMIC, THI achieved 
bactericidal effects on S. aureus, Streptococcus 
spp, E. coli, K. pneumoniae and P. aeruginosa 
at 24 hours post inoculation while ≥ 99.9% 
reduction in survival from the original inoculum 
was achieved for CoNS and Enterobacter spp 
at 30 hours post inoculation (Tables 3 and 4). 
 The ranges of log reduction in viable 
cell counts of GNB exposed to AML for 30 hrs 
were E. coli (0.7 to 2.30 Log10 CFU/ml), 
Enterobacter spp (0.38 to 2.0 Log10 CFU/ml), 
K. pneumoniae (0.85 to 2.23 Log10 CFU/ml) 
and P. aeruginosa 0.56 to 2.3 Log10 CFU/ml) 
(Table 4). The bactericidal activity of PRO on K. 
pneumoniae and P. aeruginosa was achieved at  
18- and 30-hours post inoculation respectively 
whereas 1.0 x 102 CFU/ml Enterobacter spp 
were still viable at 30 hours post inoculation 
(Table 4). The time kill kinetics curves of AML, 
THI and PRO (1.0 x MIC) against the bacterial 
isolates are shown in Figs 1 and 2.  
 The increase in viable cell counts of the 
GPB and GNB not exposed to AML, THI and 
PRO within the 30 hours of incubation were 
observed and presented in Tables 5 and 6. The 
viable cell count of S. aureus increased from 
5.57 to 7.79 Log10 CFU/ml, those of Strepto- 
coccus spp cells increased from 5.61 to 7.85 
Log10 CFU/ml while those of CoNS increased 
from 5.61 to 7.85 Log10 CFU/ml (Table 5). The 
increase in the viable cell count of GNB within 
the 30 hours incubation period was 5.60 to 
7.84 Log10 CFU/ml for E coli, 5.41 to 7.60 
Log10 CFU/ml for Enterobacter spp, 5.58 to 
7.72 Log10 CFU/ml for K. pneumoniae and 5.76 
to 7.86 Log10 CFU/ml for P. aeruginosa (Table 
6).    
 




















 The global emergence of multi-drug 
resistant pathogens as well as the continuing 
challenge of infectious diseases have necessi- 
tated the scientific exploration of novel, potent 
and affordable antimicrobial agents such as 
medicinal plants (5) and non-antibiotic drugs 
(6) in the management of infectious diseases. 
In this study, amlodipine (AML) demonstrated 
higher growth inhibitory activities at 5mg/ml 
concentration (50µg disk) against the GPB                
(S. aureus, CoNS, Streptococcus spp) and GNB 
(E. coli, Enterobacter spp, K. pneumoniae and 
P. aeruginosa) than at 2.5mg/ml concentration 
(25µg), indicating a concentration-dependent 
inhibition of bacterial growth.   
 The antibacterial activity of AML in this 
study substantiates the findings of Kumar et 
al., (8) that AML, a calcium channel blocker 
and cardiovascular drug, exhibited antibacterial 
activities against S. aureus, E. coli and P. 
aeruginosa. The antibacterial activities of AML 
on both GPB and GNB indicated its broad-
spectrum activity and these findings concurs 
with the reports of Mazumdar et al., (17) and 
Pereira et al., (18), which reported broad-
spectrum antibacterial activities of AML. The 
pattern of time-kill kinetics, investigated by the 
microbroth kinetic growth assay, against the 
GPB and GNB showed that AML exhibited 
bactericidal activities (≥ 99.9% reduction in 





survival from the original inoculum) within 
30 hours of exposure against the bacteria. 
These bactericidal activities of AML against the 
isolates in this study confirmed the findings 
previously reported by Kumar et al., (8) and 
Mazumdar et al., (17).     
 The MBC values of THI for the isolates 
ranged between 25 and 100µg/ml with bacteri- 
cidal effects on S. aureus, Streptococcus spp, 
E. coli, K. pneumoniae and P. aeruginosa at              
≤ 24 hours post inoculation. The antibacterial 
activities of THI on GPB and GNB in this study 
corroborates the findings of Radhakrishnan et 
al., (19) on the potentiality of THI as an effec- 
tive antibacterial agent. Our findings on anti- 
bacterial efficacy of THI on P. aeruginosa was 
also in conformity with a previous study by 
Mukherjee et al., (20), who reported that THI, 
an anti-psychotic drug, was a highly promising 
agent in the treatment of acute infections 
caused by P. aeruginosa. Studies have shown 
that THI exerts a bactericidal effect on bacteria 
by damaging the cell wall and causing major 
changes in expression of many genes involved 
in peptidoglycan biosynthesis (21). THI has 
also been reported to reverse antibiotic resis- 
tance by facilitating the elimination of resis- 
tance (R) plasmid from MDR bacteria (14,19).  
 In this study, PRO also exhibited anti- 
bacterial activities on both GPB and GNB, with 
log reduction in viable cell counts of GPB 
exposed for 30 hours ranging from 0.13 to 
2.20 Log10 CFU/ml. Our finding substantiates 
the reports of Dasgupta et al., (22) on anti- 
bacterial activity of PRO against antibiotic 
resistant bacterial isolates. Bactericidal activity 
of PRO against S. aureus in our study also 
agrees with the findings of Dastidar et al., 
(23). PRO, a phenothiazine, acts by inhibiting 
the efflux pump that protects bacterial cell 
against harmful chemical substances (24), and 
also affects energy sources, adenosine tri- 
phosphatase (ATPase), and genes that regulate 
permeability in bacteria (25). The increased 
permeability ensures that PRO molecules get to 
the DNA sites, intercalate between the bases, 
and consequently hinder the DNA transcription 
and translation processes (26). It has also 
been reported that PRO can reverse the 




 Our study demonstrated in vitro anti- 
microbial efficacies and time kill kinetics of 
amlodipine, thioridazine and promethazine 
against pathogenic clinical bacterial isolates, 
which indicates that these non-antibiotic drugs 
may be useful therapeutic alternatives in the 
bid to reduce the burden of infectious diseases 
associated with antibiotic resistant pathogens. 
Consequent upon these findings, in vivo anti- 
bacterial studies of these non-antibiotic drugs 
are required. 
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